IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability
Psoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific inflammatory cytokines involved in the immunopathoge...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2019-11-01
|
| Series: | European Medical Journal Dermatology |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/dermatology/article/il-23-inhibitors-for-moderate-to-severe-plaque-psoriasis-a-review-of-clinical-efficacy-safety-and-tolerability/ |
| _version_ | 1818878793403596800 |
|---|---|
| author | Sima D. Amin Annika S. Silfvast-Kaiser So Yeon Paek Dario Kivelevitch Alan Menter |
| author_facet | Sima D. Amin Annika S. Silfvast-Kaiser So Yeon Paek Dario Kivelevitch Alan Menter |
| author_sort | Sima D. Amin |
| collection | DOAJ |
| description | Psoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific inflammatory cytokines involved in the immunopathogenesis of the disease. Among these, three monoclonal antibodies specifically inhibit the p19 subunit of IL-23. IL-23 is a heterodimeric cytokine consisting of two subunits: IL-23p19 and IL-23p40. IL-23 plays a key role in the immunopathogenesis of psoriasis by activating Th17 cells, leading to stimulation of downstream cytokines involved in the systemic inflammation and keratinocyte hyperproliferation observed in psoriasis. Overall, the anti-IL-23 agents demonstrate rapid clinical improvement along with a favourable safety profile. This review has analysed data on the clinical efficacy, safety, and tolerability of the three IL-23 agents (tildrakizumab, guselkumab, and risankizumab) in the treatment of moderate-to-severe plaque psoriasis. |
| first_indexed | 2024-12-19T14:19:49Z |
| format | Article |
| id | doaj.art-18d6f80fb03746fdb5a42002c8907f94 |
| institution | Directory Open Access Journal |
| issn | 2054-6211 |
| language | English |
| last_indexed | 2024-12-19T14:19:49Z |
| publishDate | 2019-11-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Dermatology |
| spelling | doaj.art-18d6f80fb03746fdb5a42002c8907f942022-12-21T20:17:49ZengEuropean Medical JournalEuropean Medical Journal Dermatology2054-62112019-11-0171112123IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and TolerabilitySima D. Amin0Annika S. Silfvast-Kaiser1So Yeon Paek2Dario Kivelevitch3Alan Menter4Department of Internal Medicine, University of California, San Francisco, California, USADepartment of Dermatology, Baylor Scott & White, Dallas, Texas, USADepartment of Dermatology, Baylor Scott & White, Dallas, Texas, USADepartment of Dermatology, Baylor Scott & White, Dallas, Texas, USADepartment of Dermatology, Baylor Scott & White, Dallas, Texas, USAPsoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific inflammatory cytokines involved in the immunopathogenesis of the disease. Among these, three monoclonal antibodies specifically inhibit the p19 subunit of IL-23. IL-23 is a heterodimeric cytokine consisting of two subunits: IL-23p19 and IL-23p40. IL-23 plays a key role in the immunopathogenesis of psoriasis by activating Th17 cells, leading to stimulation of downstream cytokines involved in the systemic inflammation and keratinocyte hyperproliferation observed in psoriasis. Overall, the anti-IL-23 agents demonstrate rapid clinical improvement along with a favourable safety profile. This review has analysed data on the clinical efficacy, safety, and tolerability of the three IL-23 agents (tildrakizumab, guselkumab, and risankizumab) in the treatment of moderate-to-severe plaque psoriasis.https://www.emjreviews.com/dermatology/article/il-23-inhibitors-for-moderate-to-severe-plaque-psoriasis-a-review-of-clinical-efficacy-safety-and-tolerability/biologicsil-23 inhibitorspsoriasis |
| spellingShingle | Sima D. Amin Annika S. Silfvast-Kaiser So Yeon Paek Dario Kivelevitch Alan Menter IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability European Medical Journal Dermatology biologics il-23 inhibitors psoriasis |
| title | IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability |
| title_full | IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability |
| title_fullStr | IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability |
| title_full_unstemmed | IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability |
| title_short | IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability |
| title_sort | il 23 inhibitors for moderate to severe plaque psoriasis a review of clinical efficacy safety and tolerability |
| topic | biologics il-23 inhibitors psoriasis |
| url | https://www.emjreviews.com/dermatology/article/il-23-inhibitors-for-moderate-to-severe-plaque-psoriasis-a-review-of-clinical-efficacy-safety-and-tolerability/ |
| work_keys_str_mv | AT simadamin il23inhibitorsformoderatetosevereplaquepsoriasisareviewofclinicalefficacysafetyandtolerability AT annikassilfvastkaiser il23inhibitorsformoderatetosevereplaquepsoriasisareviewofclinicalefficacysafetyandtolerability AT soyeonpaek il23inhibitorsformoderatetosevereplaquepsoriasisareviewofclinicalefficacysafetyandtolerability AT dariokivelevitch il23inhibitorsformoderatetosevereplaquepsoriasisareviewofclinicalefficacysafetyandtolerability AT alanmenter il23inhibitorsformoderatetosevereplaquepsoriasisareviewofclinicalefficacysafetyandtolerability |